• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Universal label-free In-process Quantification of Influenza Virus-like particles

tetano

Editor, Senior Moderator
Biotechnol J. 2017 May 17. doi: 10.1002/biot.201700031. [Epub ahead of print]
[h=1]Universal label-free In-process Quantification of Influenza Virus-like particles.[/h] Carvalho SB[SUP]1,[/SUP][SUP]2[/SUP], Moleirinho MG[SUP]1,[/SUP][SUP]2[/SUP], Wheatley D[SUP]3[/SUP], Welsh J[SUP]3[/SUP], Gantier R[SUP]4[/SUP], Alves PM[SUP]1,[/SUP][SUP]2[/SUP], Peixoto C[SUP]1,[/SUP][SUP]2[/SUP], Carrondo MJT[SUP]1,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Virus-like particles (VLPs) are becoming established as vaccines, in particular for influenza pandemics, increasing the interest in the development of VLPs manufacturing bioprocess. However, for complex VLPs, the analytical tools used for quantification are not yet able to keep up with the bioprocess progress. Currently, quantification for Influenza relies on traditional methods: hemagglutination assay or Single Radial Immunodiffusion. These analytical technologies are time-consuming, cumbersome, and not supportive of efficient downstream process development and monitoring. Hereby we report a label-free tool that uses Biolayer interferometry (BLI) technology applied on an Octet platform to quantify Influenza VLPs at all stages of bioprocess. Human (α2,6-linked sialic acid) and avian (α2,3-linked sialic acid) biotinylated receptors associated with streptavidin biosensors were used, to quantify hemagglutinin content in several mono- and multivalent Influenza VLPs. The applied method was able to quantify hemagglutinin from crude samples up to final bioprocessing VLP product. BLI technology confirmed its value as a high throughput analytical tool with high sensitivity and improved detection limits compared to traditional methods. This simple and fast method allowed for real-time results, which are crucial for in-line monitoring of downstream processing, improving process development, control and optimization.
Copyright ? 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


[h=4]KEYWORDS:[/h] Biolayer Interferometry technology; Downstream process; In-process HA quantification; Multivalent VLPs; Octet

PMID: 28514082 DOI: 10.1002/biot.201700031
 
Back
Top Bottom